Back to discover

Protein / target

Scavenger receptor cysteine-rich type 1 protein M130

Encoded byCD163Q86VB7Homo sapiensSwiss-Prot
Small-molecule tractable
Druggability
Structure with Ligand
2
Research papers

Protein at a glance

Biological role

Scavenger receptor

Strongest disease association

Joint Diseases

Via encoding gene CD163 · Genetic evidence · score 0.40

Research activity

Emerging research

2 papers · latest 2021

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage.

View complete UniProt function annotation

Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron, via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization, inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells

Subcellular location

SecretedCell membrane
Domains and Gene Ontology detail (17)

Domains & features

SRCR 1SRCR 2SRCR 3SRCR 4SRCR 5SRCR 6SRCR 7SRCR 8SRCR 9

Gene Ontology

  • Ccytosol
  • Cendocytic vesicle membrane
  • Cexternal side of plasma membrane
  • Cextracellular region
  • Cplasma membrane
  • Fscaffold protein binding
  • Fscavenger receptor activity
  • Pacute-phase response

1156 aa · 125 kDa · 4 isoforms

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene CD163

Gene-level evidence surfaced through the gene CD163that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Joint Diseases
0.40Limited support

Genetic evidence dominant · Open Targets 0.24

Stroke
0.35Limited support

Genetic evidence dominant · Open Targets 0.18

Alcohol drinking
0.26Limited support

Genetic evidence dominant · Open Targets 0.16

Glioblastoma
0.20Preliminary

Literature evidence dominant · Open Targets 0.12 · no direct causal or clinical evidence

Adenocarcinoma of Lung
0.19Preliminary

Somatic mutation evidence dominant · Open Targets 0.15

View evidence synthesis (5)
Joint DiseasesLimited support
0.40
agreement 0.260.54
Genetic99%Literature1%

Open Targets aggregate 0.24 · 2 independent evidence families

StrokeLimited support
0.35
agreement 0.210.49
Genetic69%Literature31%

Open Targets aggregate 0.18 · 2 independent evidence families

Alcohol drinkingLimited support
0.26
agreement 0.130.40
Genetic99%Literature1%

Open Targets aggregate 0.16 · 2 independent evidence families

GlioblastomaPreliminary
0.20
agreement 0.010.39
Literature66%RNA expression35%

Open Targets aggregate 0.12 · 2 independent evidence families · no direct causal or clinical evidence

Adenocarcinoma of LungPreliminary
0.19
agreement 0.050.33
Somatic mutation81%Literature15%RNA expression5%

Open Targets aggregate 0.15 · 3 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Joint Diseases0.24
Stroke0.18
Alcohol drinking0.16
Adenocarcinoma of Lung0.15
Carcinoma, Squamous Cell0.12
Neoplasms0.12
Glioblastoma0.12

Tractability

Small moleculesEmerging

Feasibility evidence (structure with ligand) — no clinical-stage drug of this modality recorded.

AntibodiesEmerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (half-life data) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (6)
SM · Structure with LigandAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMAB · Human Protein Atlas locPR · Half-life Data

Raw Open Targets tractability assessment buckets, by modality.

Research activity

2 papers · to 2021

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.

Related family literature

1

Papers about “Receptors, Scavenger” — a broader family this protein belongs to. Shown as context; not counted as papers specifically about this protein.

The Role of Macrophages in <i>Staphylococcus aureus</i> Infection.

Pidwill GR · Frontiers in immunology · 2020

via Receptors, Scavenger

Europe PMC literature, reached through curated HGNC family membership. Membership is a taxonomic relationship — it does not imply this protein participates in every mechanism these papers discuss.